Should I buy or sell Pasithea Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pasithea Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KTTA shares. View KTTA analyst ratings or view top-rated stocks .

What is Pasithea Therapeutics' stock price target for 2024?

1 brokers have issued twelve-month price targets for Pasithea Therapeutics' stock. Their KTTA share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 527.0% from the stock's current price. View analysts price targets for KTTA or view top-rated stocks among Wall Street analysts .

How have KTTA shares performed in 2023?

Pasithea Therapeutics' stock was trading at $0.6417 at the beginning of the year. Since then, KTTA shares have decreased by 50.3% and is now trading at $0.3190. View the best growth stocks for 2023 here .

When is Pasithea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our KTTA earnings forecast .

When did Pasithea Therapeutics IPO?

(KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Pasithea Therapeutics Stock Price, News & Analysis (NASDAQ:KTTA)

$0.32

-0.01 (-3.04%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.29
▼
$0.32
50-Day Range: $0.30
▼
$0.48
52-Week Range: $0.29
▼
$1.05

Volume: 32,350 shs
Average Volume: 60,902 shs
Market Capitalization: $6.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Pasithea Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 527.0% Upside
$2.00 Price Target
Short Interest: Healthy
0.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.73
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Pasithea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.00, Pasithea Therapeutics has a forecasted upside of 527.0% from its current price of $0.32.
Amount of Analyst Coverage
Pasithea Therapeutics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.24% of the float of Pasithea Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Pasithea Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pasithea Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Pasithea Therapeutics does not currently pay a dividend.
Dividend Growth
Pasithea Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KTTA.

2.1

News and Social Media Coverage

News Sentiment
Pasithea Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Pasithea Therapeutics this week, compared to 0 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.10% of the stock of Pasithea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.48% of the stock of Pasithea Therapeutics is held by institutions.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
Pasithea Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

KTTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KTTA Stock News Headlines

November 29, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

November 29, 2023 | msn.com

Pasithea stock jumps 12% on update for anti-tumor drug PAS-004

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 29, 2023 | markets.businessinsider.com

Pasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical Development

November 29, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

November 9, 2023 | finance.yahoo.com

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

September 14, 2023 | finance.yahoo.com

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

September 7, 2023 | finance.yahoo.com

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

August 1, 2023 | finance.yahoo.com

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function

July 20, 2023 | benzinga.com

What's Happening With Pasithea Therapeutics Stock Today?

July 20, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

July 20, 2023 | finance.yahoo.com

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

July 20, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

June 30, 2023 | finance.yahoo.com

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

June 29, 2023 | finance.yahoo.com

Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

June 5, 2023 | barrons.com

Pasithea Therapeutics Corp.

June 1, 2023 | finanznachrichten.de

Financialnewsmedia.com: Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

June 1, 2023 | finance.yahoo.com

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

May 14, 2023 | finance.yahoo.com

Pasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022)

May 3, 2023 | finance.yahoo.com

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

April 1, 2023 | seekingalpha.com

Pasithea Therapeutics files for $15M mixed shelf offering

March 2, 2023 | finance.yahoo.com

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

February 23, 2023 | finance.yahoo.com

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

February 16, 2023 | finance.yahoo.com

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

January 25, 2023 | seekingalpha.com

KTTA Pasithea Therapeutics Corp.

January 18, 2023 | finance.yahoo.com

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

See More Headlines

Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KTTA
CUSIP: N/A
CIK: 1841330
Web: www.pasithea.com
Phone: 702-514-4174
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.00
High Stock Price Target: $2.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +527.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,940,000.00
Net Margins: N/A
Pretax Margin: -3,436.96%
Return on Equity: -45.98%
Return on Assets: -42.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.16
Quick Ratio: 10.16

Sales & Book Value

Annual Sales: $490,000.00
Price / Sales: 13.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.36 per share
Price / Book: 0.23

Miscellaneous

Outstanding Shares: 20,840,000
Free Float: 17,899,000
Market Cap: $6.65 million
Optionable: Not Optionable
Beta: 0.71

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Lawrence Steinman BA (Age 75)
M.D., Ph.D., Executive Chairman & Co-Founder
Comp: $250k
Dr. Tiago Reis Marques M.D. (Age 46)
Ph.D., CEO & Director
Comp: $539.25k
Mr. Daniel H. Schneiderman (Age 45)
Chief Financial Officer
Comp: $327.91k
Dr. Yassine Bendiabdallah Ph.D. (Age 38)
COO & Head of UK Clinics
Dr. Graeme Currie Ph.D.
Chief Development Officer

Key Competitors

View All Competitors

Insiders

Lawrence Steinman
Bought 30,000 shares on 6/2/2023
Total: $12,900.00 ($0.43/share)

View All Insider Transactions

KTTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Pasithea Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pasithea Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KTTA shares.
View KTTA analyst ratings or view top-rated stocks.
What is Pasithea Therapeutics' stock price target for 2024?: 1 brokers have issued twelve-month price targets for Pasithea Therapeutics' stock. Their KTTA share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 527.0% from the stock's current price.
View analysts price targets for KTTA or view top-rated stocks among Wall Street analysts.
How have KTTA shares performed in 2023?: Pasithea Therapeutics' stock was trading at $0.6417 at the beginning of the year. Since then, KTTA shares have decreased by 50.3% and is now trading at $0.3190.
View the best growth stocks for 2023 here.
When is Pasithea Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our KTTA earnings forecast.

When did Pasithea Therapeutics IPO?: (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.
How do I buy shares of Pasithea Therapeutics?: Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KTTA) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pasithea Therapeutics Stock Price, News & Analysis (NASDAQ:KTTA)

Pasithea Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

KTTA Stock Price History

KTTA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

KTTA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™